To validate our hypothesis that blocking CCR5+ T cell accumulation improves YM101 efficacy, we evaluated the antitumor effects of CCR5 inhibitor (CCR5i) Maraviroc in combination with YM101 in multiple murine tumor models. This evidence concerns the gene CCR5 and neoplasm.